Navigation Links
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
Date:2/13/2008

lucosidase alfa),

which has been constrained by limited product supply, as the FDA has

yet to approve the larger scale manufacturing process for this product.

This supply constraint will have an estimated impact of $0.03 per

diluted share during the first quarter.

Product Sales

-- Sales of Myozyme are expected to increase to $320-$330 million this

year, compared with $201 million last year. The launch of this product

has been the most rapid for any of Genzyme's lysosomal storage disorder

treatments. In December, Genzyme announced that its post-marketing

Late-Onset Treatment Study of Myozyme met its co-primary endpoints,

confirming the benefit of the product for patients across the spectrum

of Pompe disease. The company has begun submitting the results of this

study for presentation at medical meetings and will pursue the

inclusion of the trial results in the product's labeling.

-- Sales of Fabrazyme(R) (agalsidase beta) are expected to reach $495-$505

million this year, compared with $424 million in 2007. The European

Commission has granted full marketing authorization for Fabrazyme,

making the product the only Fabry disease treatment to earn this

designation in Europe.

-- Sales of Cerezyme(R) (imiglucerase for injection) are expected to reach

$1.22-$1.24 billion this year, compared with $1.13 billion in 2007.

-- Sales of sevelamer therapies Renagel(R) (sevelamer hydrochloride) and

Renvela(R) (sevelamer carbonate) are expected to rise to $690-$700

million this year, compared with $603 million in 2007. Renvela was

approved by the FDA in October for the treatment of hemodialysis

patients, and Genzyme plans to launch the product on March 1. Genzyme

is currently engaged in active discussions with the FDA to expand the

product'
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. Genzyme Receives FDA Response Letter on Synvisc-One(TM)
2. Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
3. Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
4. Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
5. Delaware Court Approves Bioenvision, Genzyme Joint Petition
6. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
7. Liquent Insight Publisher 3.6 Delivers Advanced Submission Capabilities
8. March of Dimes Delivers a New Look
9. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
11. Gleevec, the targeted cancer pill, delivers more good news to patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Therapy Association Annual Conference to be held May ... SC. , The SCAPTA Annual Conference offers ... and services. , Representatives from Aureus Medical’s ...
(Date:4/18/2015)... FL (PRWEB) April 18, 2015 PHOENIX, ... Hillsborough County, along with 11 other secure destruction professionals ... Secure Destruction Specialists (CSDS). He will now display “CSDS” ... exams were offered before the National Association of Information ... Illinois and another Grapevine, Texas. Of the 20 people ...
(Date:4/17/2015)... Heritage Woods of McLeansboro, a Gardant affordable ... Celebration on April 20 with a day full of ... and soul. , The community, which is located at ... of all incomes, including those on Medicaid, who need ... Week is observed every April and highlights the communities ...
(Date:4/17/2015)... Rosetta Radiology is proud to now offer ... of diagnostic imaging services. This solidifies them as a ... East Side of Manhattan. , The new imaging equipment ... of PET-CT, combined with Rosetta’s state of the art ... with patients through several stages of the cancer care ...
(Date:4/17/2015)... Riviera Magazine has featured board ... the Gallery of Cosmetic Surgery in Newport Beach, California ... The publication focused on his expertise in the lower ... eyelid surgery, laser resurfacing and rhinoplasty. , Dr. Sadati’s ... resulted in thousands of satisfied patients across the globe. ...
Breaking Medicine News(10 mins):Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 2Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 3
... nongovernmental organizations has published a report proposing a set ... asthma clinical research. Asthma Outcomes in Clinical Research: Report ... supplement to the March 2012 issue of the ... a meeting organized by the National Institutes of Health, ...
... March 2 (HealthDay News) -- Women become less likely to ... year of college, new research finds. Declining condom use ... worse grades and who came from poorer backgrounds. "We ... pregnancies and sexually transmitted diseases, yet there has been a ...
... memory is observed in people who consume drugs containing ... team led by Giovanni Marsicano (Inserm Research Unit 862) ... has recently identified the mechanism by which these substances ... first time that the adverse effect of cannabinoids on ...
... Survivors of cancer in childhood have a higher risk ... reached by Magdalena Balcerek and her co-authors in a ... Arztebl Int 2012; 109[7] 126-31). , In a nationwide ... childhood and adolescence, the authors collected data from former ...
... Reinberg HealthDay Reporter , THURSDAY, March 1 (HealthDay ... for cervical cancer are more likely to survive if they ... suggests. Compared to women whose cervical cancer is detected ... increased their cure rate from 66 percent to more than ...
... the 27,000 plus people around the world who donate a ... donors for 10 years found that they were at no ... Led by Dr. Amit Garg, a researcher ... Sciences Centre, the results provide important safety reassurances to donors, ...
Cached Medicine News:Health News:Standardized outcome measures proposed for asthma clinical research 2Health News:College Women's Condom Use Falls During Freshman Year 2Health News:How does cannabis affect working memory? 2Health News:How does cannabis affect working memory? 3Health News:Regular Pap Smear Boosts Cervical Cancer Survival: Study 2Health News:Regular Pap Smear Boosts Cervical Cancer Survival: Study 3Health News:First study of its kind finds no increased risk of heart disease for kidney donors 2
(Date:4/17/2015)... , Apr. 16, 2015 Research and Markets ... addition of the "The Corporate Reputation of ... Global Edition " report to their offering. ... Patient Perspective, is now in its fourth edition. ... published early 2015). For each annual Corporate Reputation ...
(Date:4/16/2015)... WASHINGTON , April 16, 2015 Vanda ... company focused on the development and commercialization of products ... announced it will release results for the first quarter ... market closes. The Company will host ... May 6, 2015, during which Vanda management will discuss ...
(Date:4/16/2015)... Calif. , April 16, 2015  Amgen (NASDAQ: ... its first quarter financial results on Tuesday, April 21, ... The announcement will be followed by a conference call ... in the call from Amgen will be Robert ... other members of Amgen,s senior management team. ...
Breaking Medicine Technology:The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2Amgen Announces Webcast Of 2015 First Quarter Financial Results 2
... the public about the,need and benefits of angioplasty, ... onslaught of,anti-stent news reports over the past few ... work and its use should,decrease. Confused by the ... the benefits of stenting. , "Doctor and patient ...
... /PRNewswire-FirstCall/ -- Vanda,Pharmaceuticals Inc. announced today that Dr. ... and Research Center in Detroit, MI,will deliver an ... for VEC-162, Vanda's balanced melatonin (MT1/MT2),receptor agonist, at ... Professional Sleep Societies, (APSS). , The Vanda presentation ...
Cached Medicine Technology:To Stent or Not: Is That the Question? 2Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the,Annual Meeting of the Associated Professional Sleep Societies 2
The rotating stage assembly is designed to give the researcher maximum flexibility in the mounting of specimens. It can be turned to any horizontal and vertical angle via a ball joint mounting arran...
The glass knife adapter allows for the use of glass knives or ralph knives on the Vibratome. The adapter can be installed in place of the standard razor blade mounting device....
Inquire...
Inquire...
Medicine Products: